Further study of the relationship between PAX3 expression in melanoma CTCs with early response to MAPK inhibitors, in a larger cohort of patients, may provide an insight into its role in the development of acquired resistance and its biomarker utility. The gene discussed is PAX3; the disease is melanoma.